Small-Molecule Activators of PRMT1: Discovery, SAR Analyses, and Proapoptotic Effects in Pancreatic Cancer Cells

Abstract A substantial body of research implicates PRMTs in the pathogenesis of human diseases, primarily as oncoproteins or tumor suppressors in cancer. Starting from structure-based in silico screening of small-molecule databases, we predicted, synthesized, and assayed compounds aimed at specifically inhibiting selected PRMT family members. Unexpectedly, among several PRMT-inhibitory molecules we identified TR-07, a compound that selectively enhances the catalytic activity of PRMT1 in vitro. SAR analyses led to the design and synthesis of derivatives with increased potency in activating PRMT1 compared to TR-07 but at the cost of selectivity. TR-07 and its derivatives bind to the αY helix near the catalytic core of PRMT1. Treatment of pancreatic tumor cells with these PRMT1 activators enhanced global ADMA levels and augmented PRMT1’s apoptotic function in cell culture and mouse models. Our results establish TR-07 as the first selective, cell-active PRMT1 activator and underscore the therapeutic promise of this novel class of modulators.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-08-20
DOI
https://doi.org/10.1021/acs.jmedchem.5c03281
Primary Topic
Cancer-related gene regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Small-Molecule Activators of PRMT1: Discovery, SAR Analyses, and Proapoptotic Effects in Pancreatic Cancer Cells

Van Tuan Trinh, Uta‐Maria Bauer, Wibke E. Diederich, Katrin Roth et al.
Journal of Medicinal Chemistry
Cancer-related gene regulation
article

Small-Molecule Activators of PRMT1: Discovery, SAR Analyses, and Proapoptotic Effects in Pancreatic Cancer Cells

Van Tuan Trinh, Uta‐Maria Bauer, Wibke E. Diederich, Katrin Roth, Michael Daude, Anett Hauser, Jörg W. Bartsch, David Vonhören, Gert Bange, Peter Kolb, Sinja Rakow, Frank Abendroth, Detlef K. Bartsch, Felix Terwesten, Olalla Vázquez, Wieland Steinchen, Daniel Hilger, Christian Iking, Marion Meixner, Stefanie Dörr, Sepideh Salehipour-Bavarsad, Jonas Kammertöns, Gina Bach, Caroline Bouchard, Sona Martirosian, Anne Kagerhuber, Johanna Senst
article en

Abstract

Abstract A substantial body of research implicates PRMTs in the pathogenesis of human diseases, primarily as oncoproteins or tumor suppressors in cancer. Starting from structure-based in silico screening of small-molecule databases, we predicted, synthesized, and assayed compounds aimed at specifically inhibiting selected PRMT family members. Unexpectedly, among several PRMT-inhibitory molecules we identified TR-07, a compound that selectively enhances the catalytic activity of PRMT1 in vitro. SAR analyses led to the design and synthesis of derivatives with increased potency in activating PRMT1 compared to TR-07 but at the cost of selectivity. TR-07 and its derivatives bind to the αY helix near the catalytic core of PRMT1. Treatment of pancreatic tumor cells with these PRMT1 activators enhanced global ADMA levels and augmented PRMT1’s apoptotic function in cell culture and mouse models. Our results establish TR-07 as the first selective, cell-active PRMT1 activator and underscore the therapeutic promise of this novel class of modulators.

Journal of Medicinal Chemistry
Philipps University of Marburg (DE), Universitätsklinikum Gießen und Marburg (DE)
José Carreras Leukämie-Stiftung
Good health and well-being
Openalex Percentile: Top 16%
Cancer-related gene regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.